1. Pink Sheet
  2. >>Product Reviews

US FDA’s Cavazzoni Says Retaining Virtual Meetings Could Improve Communications Going Forward

 
• By Derrick Gingery

One of the lessons learned from the pandemic may be that virtual meetings can be used in place of an in-person session more often.

Virtual meeting
Virtual meetings could help increase the frequency of FDA-sponsor interactions after the pandemic. • Source: Alamy

Virtual meetings may remain a significant part of the US Food and Drug Administration’s strategy post-pandemic to improve its communications with sponsors.

Center for Drug Evaluation and Research Director Patrizia Cavazzoni said the increased flexibility allowed by virtual meetings should be a consideration for sponsors even after staff return to their offices...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.